

4th Academy Meeting of National Brain Councils
17th – 18th April 2018
Champalimaud Foundation, Avenida Brasília, Lisbon

In partnership with the European Federation of Neurological Associations (EFNA)

Tuesday 17th April-----

Morning: arrival to Lisbon

13.00 Informal welcome lunch in the Champalimaud Foundation

14.00 – 17.30 **NBCs Academy 1st session**

14.00 Setting the scene and progress update, including European Brain Research
Area project application and EU Framework Programmes

Frédéric Destrebecq, EBC Executive Director

14.30 National Brain Plans – case study based on the Norwegian Brain Plan
launched in December 2017 and update from Poland

Anette Størstein and Aud Kvalbein, Norwegian Brain Council

Iza Czarnecka – Walicka, Polish Brain Council

15.00 Questionnaire on the state of national brain health care

Roland Pochet, Belgian Brain Council and Iza Czarnecka, Polish Brain Council

15.20 Coffee break

15.50 Value of Treatment – general update, dissemination and future plans

Patrice Boyer, European Brain Council

16.40 Discussion - proposed topics include:

- elections of NBC delegates to the EBC Board
- progress updates from NBCs
- possibility of organizing regional NBCs meetings (e.g. Nordic region)

17.30 Shuttle to the hotel (Holiday Inn Lisbon Continental)

19.30 Joint dinner with EFNA, A Casa do Bacalhau, Rua do Grilo 54
(shuttle service will be provided)

Wednesday 18th April

9.00 Shuttles depart hotel

9.30 EFNA/EBC Joint Session: The Future of Health Technology
Assessment in Europe

Moderated by: **John Bowis, former MEP, former UK Health Minister
and EBC Honorary Member**

Opening remarks: **Alexandre Quintanilha, President of the Portuguese Parliamentary
Commission for Education and Science**

Value of Treatment for Brain Disorders

Question: How do we foster a new paradigm in value based, innovative patient
centred healthcare?

Patrice Boyer, Vice – President, EBC

Followed by views from:

- The European Policy-Maker
**Flora Giorgio, Head of Sector Health Technology Assessment, European
Commission**
- The Industry
**Nuno Silverio, Director of Market Access & Governmental Affairs, Merck
Caroline Daly, Associate Director, Public Affairs | Patient Advocacy, Biogen**
- The Patient
**Donna Walsh, Executive Director, European Federation of Neurological
Associations**
- The National Regulator
**Maria do Céu Machado, President, INFARMED - National Authority of
Medicines and Health Products**

11.10– 11.40 Coffee break

11.40 – 12.30 Discussion: Recommendations and Conclusions
How do we ensure HTA reflects the real value of treatment for
brain disorders?

12.30 Tour of the Champalimaud Foundation, followed by lunch and
departure